Gender differences in the IL6 -174G>C and ESR2 1730G>A polymorphisms and the risk of Parkinson's disease

Neuroscience Letters

Volumn 506, Issue 2, 2012, Pages 312-316

  San Luciano, M ^a   Ozelius, L ^b   Lipton, R B ^c   Raymond, D ^a   Bressman, S B ^a   Saunders Pullman, R ^a,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Estrogen receptor; Gender; Inflammation; Interleukin 6; Parkinson's disease; Polymorphism

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; INTERLEUKIN 6;

AGED; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC LOAD; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ESTROGEN RECEPTOR BETA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; MALE; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84655169613     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.11.032     Document Type: Article

References (42)

1. Alam Z.I., Daniel S.E., Lees A.J., Marsden C.D., Jenner P., Hallwell B. A generalized increase in protein carbonyls in the brain of Parkinson's but no incidental Lewy body disease. J. Neurochem. 1997, 69:1326-1329.
2. Baldereschi M., DiCarlo A., Rocca W., Vanni P., Maggi S., Perissinotto E., Amaduci F. Parkinson's disease and parkinsonism in a longitudinal study, two fold higher incidence in men. Neurology 2000, 55:1358-1363. D. Inzitari and for the ILSA Working Group.
3. 11C]-PK11195 PET. Mov. Disord. 2007, 22:1852-1856.
4. Benedetti M.D., Maragarone D.M., Bower J.H., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., Rocca W.A. Histerectomy, menopause and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov. Disord. 2001, 16:830-837.
5. Bonafe M., Olivieri F., Cavallone L., Giovagnetti S., Mayegiani F., Cardell M., Pieri C., Marra M., Antonicelli R., Lisa R., Rizzo M.R., Paolisso G., Monti D., Franceschi C. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur. J. Immunol. 2001, 31:2357-2361.
6. Brodacki B., Staszewski J., Tczylowska B., Kozlowska E., Drela N., Chalimoniuk M., Stepien A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF-α, and INFγ concentrations are elevated in patients and atypical and idiopathic parkinsonism. Neurosci. Lett. 2008, 441:158-162.
7. Brull D.J., Montgomery H.E., Sanders J., Dhamrait S., Luong L., Rumley A., Lowe G.D.O., Humphries S.E. Interleukin-6 gene -174G>C and -572G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1458-1463.
8. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10061-10065.
9. Chen H.L., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., Ascherio A. Nonsteroidal anti-inflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 2005, 58:963-967.
10. Chen H.L., Zhang S.M.M., Hernan M.A., Schwarzchild M.A., Willet W.C., Colditz G.A., Speizer F.E., Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch. Neurol. 2003, 60:1059-1064.
11. Cussigh A., Falleti E., Fabris C., Bitetto D., Cmet S., Fontani E., Bignulin S., Fumolo E., Minisini R., Pirisi M., Toniutto P. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics 2011, 63:33-41.
12. Ferrari S.L., Garnero P., Emmond S., Montgomery H., Humphries S.E., Greenspan S.L. A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. Arthritis Rheum. 2001, 44:196-201.
13. Fishman D., Faulds G., Jeffery R., Mohammed-Ali V., Yudki J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and associated with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102:1369-1376.
14. Garcia-Segura L.M., Azcoitia I., DonCarlos L. Neuroprotection by estradiol. Prog. Neurobiol. 2001, 63:29-60.
15. Gasser T. Update on genetics of Parkinson's disease. Mov. Disord. 2007, 22:S343-S350.
16. Hakansson A., Westberg L., S.Nilsson, Buervenich S., Carmine A., Holmberg B., Sydow O., Olson L., Johnels B., Eriksson E., Nisbrandt H. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor Beta on the susceptibility to Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 133B:88-92.
17. Hama T., Kushima Y., Miyamoto M., Kubota M., Takei N., Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rat in cultures. Neuroscience 1991, 40:445-452.
18. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
19. Hunot S., Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S49-S60.
20. Infante J., Garcia-Gorostiaga I., Sanchez-Juan P., Sanchez-Quintana C., Gurpegui J.L., Rodriguez-Rodriguez E., Mateo I., Berciano J., Combarros O. Inflammation-related genes and the risk of Parkinson's disease: a multilocus approach. Eur. J. Neurol. 2008, 15:431-433.
21. International Parkinson Disease Genomics Consortium Imputation of sequence variants for identification of genetic risks for Parkinson disease: a meta-analysis of genome-wide association studies. Lancet 2011, (early online publication).
22. Jones K.G., Brull D.J., Brown L.C., Sian M., Greenhalgh R.M., Humphries S.E., Powell J.T. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001, 103:2260-2265.
23. Klein C., Schlossmacher M.G. The genetics of Parkinson's disease: implications for neurological care. Nat. Clin. Pract. Neurol. 2006, 2:136-146.
24. Kristiansen O.D., Nolsoe R.L., Larsen L., Gjesing A.M., Johannesen J., Larsen Z.M., Lykkesfeldt A.E., Karlsen A.E., Pociot F., Mandrup-Poulsen T., DIEGG, DSGD Association of a functional 17-beta-estradiol sensitive IL6 174 G/C polymorphism with early onset type 1 diabetes mellitus in females. Hum. Mol. Genet. 2003, 12:1101-1110.
25. Kruger R., Hardt C., Tschentscher F., Jackel S., Juhn W., Muller T., Werner J., Woitalla D., Berg D., Kuhnk N., Fuchs G.A., Santos E.J., Przuntek H., Epplen J.T., Schols L., Riess O. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. J. Neural Transm. 2000, 107:553-562.
26. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
27. Muller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol. Scand. 1998, 98:142-144.
28. Olivieri F., Bonafe M., Cavallone L., Giovagnetti S., Marchegianim F., Cardelli M., Mugianesi E., Giamperi C., Moresi R., Stecconi R., Lisa R., Franceschi C. The -174C/G/locus affects in vitro/vivo IL-6 production during aging. Exp. Gerontol. 2002, 37:309-314.
29. Pottratz S.T., Bellido T., Mocharla H., Crabb D., Manolagas S.C. 17β-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 1994, 93:944-950.
30. Putnik M., Zhao C., Gustafsson J.A., Dahlman-Wright.K. Effects of two common polymorphisms in the untranslated regions of estrogen receptor beta on mRNA stability and translatability. BMC Genet. 2009, 55.
31. Ragland M., Hutter C., Zabetian C., Edwards K. Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's disease: a HuGE review and metaanalysis. Am. J. Epidemiol. 2009, 170:1344-1357.
32. Ray P., Ghosh S.K., Zhang D.H., Ray A. Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NK-kappa B by the estrogen receptor. FEBS Lett. 1997, 409:79-85.
33. Rea I., Ross O.A., Armstrong M., McNerlan S., Alexander D.H., Curran M.D., Middleton D. Interleukin-6-gene C/G 174 polymorphism in nonagenarian and octogenarian subjects in the BELFAST study. Reciprocal effects on IL-6, soluble IL-6 receptor and for IL-10 in serum and monocyte supernatants. Mech. Ageing Dev. 2003, 124:555-561.
34. Rocca W.A., Bower J.H., Maraganore D.M., Ahlskog J.E., Grossardt B.R., de Andrade M., Melton L.J. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008, 70:200-209.
35. Ross O.A., O'Neill C., Rea I.M., Lynch T., Gosal D., Wallace A., Curran M.D., Middleton D., Gibson J.M. Functional promoter region polymorphism of the proinflammatory chemokine IL-6 gene associates with Parkinson's disease in the Irish. Hum. Immunol. 2004, 65:340-346.
36. Saunders-Pullman R. Estrogens and Parkinson's disease: neuroprotective, symptomatic, neither, or both?. Endocrine 2003, 21:81-87.
37. Saunders-Pullman R., Stanley K., San Luciano M., Barrett M.J., Shanker V.L., Raymond D., Ozelius L., Bressman S. Gender differences in the risk of familial parkinsonism: beyond LRRK2?. Neurosci. Lett. 2011, 496:125-128.
38. Scalzo P., Kummer A., Cardoso F., Texeira A.L. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci. Lett. 2010, 469:56-58.
39. Tanner C.M., Ottman R., Goldman S.M., Ellenberg J., Chan P., Mayeux R., Lansgton J.W. Parkinson disease in twins: an etiologic study. JAMA 1999, 281:341-346.
40. Vegeto E., Bonincontro C., Pollio G., Sala A., Viappiani S., Nardi F., Brusadelli A., Viviani B., Ciana P., Maggo A. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J. Neurosci. 2001, 21:1809-1818.
41. Westberg L., Hakansson A., Melke J., Niazi Shahabi H., Nilsson S., Buervenich S., Carmine A., Ahlberg J., Grundell M.B., Schulhof B., Klingborg K., Holmberg B., Sydow O., Olson L., Johnels E.B., Eriksson E., Nissbrandt H. Association between the estrogen receptor beta gene and onset of Parkinson's disease. Psychoneuroendocrinology 2004, 29:993-998.
42. Zhou C., Huang Y., Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 2008, 1147:93-104.